DOI: https://doi.org/10.36347/sajp.2024.v13i07.006

Pages: 332-336

Background: Asthma is a chronic inflammatory condition that significantly affects patients' quality of life and poses a substantial healthcare burden. Inhaled corticosteroids (ICS) are a primary treatment modality, yet variations in treatment objectives between patients and healthcare providers necessitate a collaborative approach to asthma management. Objective: This review aims to evaluate the efficacy and safety of different ICS formulations and combination therapies in managing asthma and to identify optimal treatment strategies that align with both clinical guidelines and patient preferences. Methodology: A systematic search of the MEDLINE database was conducted to identify studies published from 2019 to the present, focusing on the safety and efficacy of ICS in asthma therapy. Out of 106 initial results, 11 studies (including controlled and randomized controlled trials) met the inclusion criteria for review. Results: The analysis revealed that the timely administration of ICS can significantly reduce emergency room visits and hospitalizations during acute exacerbations. Studies highlighted the comparative advantages of various ICS, such as fluticasone furoate's enhanced airway protection and the effectiveness of self-titration strategies in managing symptoms. Combination therapies involving ICS improved asthma control and lung function, particularly in patients with moderate to severe asthma and those with asthma-COPD overlap. Implications: The findings underscore the importance of individualized ICS therapy, suggesting that tailored treatment regimens can enhance clinical outcomes and patient adherence. Integrating patient feedback into treatment decisions is essential for optimizing asthma management strategies.